Police & Firemen s Retirement System of New Jersey Raises Stake in Elanco Animal Health Incorporated $ELAN

Police & Firemen s Retirement System of New Jersey boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 6.5% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 189,508 shares of the company’s stock after buying an additional 11,556 shares during the quarter. Police & Firemen s Retirement System of New Jersey’s holdings in Elanco Animal Health were worth $2,706,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. First Horizon Advisors Inc. lifted its position in Elanco Animal Health by 184.3% during the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after purchasing an additional 2,414 shares during the period. Wealthquest Corp acquired a new stake in Elanco Animal Health during the 1st quarter worth about $56,000. Caitong International Asset Management Co. Ltd raised its stake in shares of Elanco Animal Health by 261.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock valued at $58,000 after buying an additional 2,922 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Elanco Animal Health by 510.9% in the 1st quarter. Covestor Ltd now owns 7,087 shares of the company’s stock valued at $74,000 after buying an additional 5,927 shares during the period. Finally, MRP Capital Investments LLC boosted its stake in shares of Elanco Animal Health by 60.0% in the first quarter. MRP Capital Investments LLC now owns 8,000 shares of the company’s stock worth $84,000 after buying an additional 3,000 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Trading Down 0.2%

Shares of NYSE:ELAN opened at $21.39 on Wednesday. The firm has a market capitalization of $10.63 billion, a price-to-earnings ratio of 356.48, a price-to-earnings-growth ratio of 2.91 and a beta of 1.71. The business’s 50 day moving average price is $20.68 and its 200-day moving average price is $16.87. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.40 and a quick ratio of 1.23. Elanco Animal Health Incorporated has a 1 year low of $8.02 and a 1 year high of $23.09.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same period in the prior year, the business posted $0.13 earnings per share. The firm’s revenue for the quarter was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS. Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Piper Sandler lifted their price target on Elanco Animal Health from $12.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, August 11th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Thursday, November 13th. JPMorgan Chase & Co. upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $18.00 to $24.00 in a research note on Tuesday, October 7th. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, November 6th. Finally, Wall Street Zen raised shares of Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.29.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.